Pay in 4 interest-free payments of $6.82 Learn more
)
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
3 Ways GLP-1 Drugs Could Impact Your Hospitals Future Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand
The Tirzepatide Advantage Unlike single-target medications, tirzepatide activates both GLP-1 and GIP receptors, offering: Anti-inflammatory effects: Reduces inflammatory cytokines and shifts immune responses toward healing Metabolic benefits: Improves insulin sensitivity and glucose metabolism Tissue-level changes: Stimulates thermogenesis and reduces fibrosis Enhanced fat mobilization: May help mobilize stubborn lipedematous fat stores Clinical Evidence: Early Promise A recent case series treated five women with lipedema using exenatide (a GLP-1 agonist) for 3-6 months, showing: Reduced pain and tenderness in affected areas Decreased tissue thickness measured by ultrasound Improved symptoms even without significant weight loss Better tissue consistency and reduced inflammation Crucially, improvements occurred even in patients who didnt lose weight, suggesting direct effects on lipedematous tissue beyond weight management
These symptoms can make daily activities hard and affect overall health
Rybelsus Rybelsus is the tablet form of semaglutide approved for type 2 diabetes management
doi: 10.1016/j.neuropharm.2014.09.019 222 ZhangZWangXZhangDLiuYLiL
249 Ubiquitination of RIP1 reduces NF-B activity and inhibits melanoma growth, underscoring the role of the UPS in regulating oncogenic signaling pathways
